Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and Apoptosis
- 12 March 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 7 (3), 2860-2871
- https://doi.org/10.1021/nn400548g
Abstract
Tumor microenvironment, such as the lowered tumor extracellular pH (pHe) and matrix metalloproteinase 2 (MMP2), has been extensively explored, which promotes the development of the microenvironment-responsive drug delivery system. Utilizing these unique features, an activatable cell-penetrating peptide (designated as dtACPP) that is dual-triggered by the lowered pHe and MMP2 has been constructed, and a smart nanoparticle system decorating with dtACPP has been successfully developed, which could dual-load gene drug and chemotherapeutics simultaneously. After systemic administration, dtACPP-modified nanoparticles possess passive tumor targetability via the enhanced permeability and retention effect. Then dtACPP would be activated to expose cell-penetrating peptide to drive the nanoparticles' internalization into the intratumoral cells. As angiogenesis and tumor cells might be mutually improved in tumor growth, so combining antiangiogenesis and apoptosis is meaningful for oncotherapy. Vascular endothelial growth factor (VEGF) is significant in angiogenesis, and anti-VEGF therapy could decrease blood vessel density and delay tumor growth obviously. Chemotherapy using doxorubicin (DOX) could kill off tumor cells efficiently. Here, utilizing dtACPP-modified nanoparticles to co-deliver plasmid expressing interfering RNA targeting VEGF (shVEGF) and DOX (designated as dtACPPD/shVEGF-DOX) results in effective shutdown of blood vessels and cell apoptosis within the tumor. On the premise of effective drug delivery, dtACPPD/shVEGF-DOX has demonstrated good tumor targetability, little side effects after systemic administration, and ideal antitumor efficacy.Keywords
This publication has 44 references indexed in Scilit:
- Phosphatidylserine targeting for diagnosis and treatment of human diseasesApoptosis, 2010
- Systemicin vivodistribution of activatable cell penetrating peptides is superior to that of cell penetrating peptidesIntegrative Biology, 2009
- In vivo fluorescence imaging: a personal perspectiveWIREs Nanomedicine and Nanobiotechnology, 2009
- Recent progress in tumor pH targeting nanotechnologyJournal of Controlled Release, 2008
- Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndromeProceedings of the National Academy of Sciences of the United States of America, 2008
- Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingProceedings of the National Academy of Sciences of the United States of America, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Cell Death: Critical Control PointsCell, 2004
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002